You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
億帆醫藥(002019.SZ):艾貝格司亭α注射液收到藥品補充申請批準通知書
格隆匯 03-21 19:15

格隆匯3月21日丨億帆醫藥(002019.SZ)公佈,控股子公司億一生物製藥(北京)有限公司於2025年3月21日收到國家藥品監督管理局覈準簽發的艾貝格司亭α注射液(簡稱“億立舒”)《藥品補充申請批準通知書》。本次億立舒給藥時間由化療結束48小時後變更爲化療結束24小時後的補充申請獲得批準後,公司產品億立舒將更具差異化競爭優勢,有助於拓展市場份額,提升品牌影響力。同時,化療後給藥時間的變更,患者可以更早接受億立舒注射,符合臨牀需求和實踐,從而提高患者用藥依從性,減少可能的住院時間及醫療費用,提升醫療資源的利用效率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account